{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:24:31Z","timestamp":1791181471529,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,12,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> The randomized First-Line Indolent Trial (FIT) was conducted in patients with advanced follicular lymphoma (FL), to evaluate the safety and efficacy of yttrium-90 (<jats:sup>90<\/jats:sup>Y) ibritumomab tiuxetan given as consolidation of complete or partial remission. This study of minimal residual disease was undertaken in parallel, to determine the rate of conversion from bcl-2 polymerase chain reaction (PCR) \u2013detectable to \u2013undetectable status and the corresponding effect on progression-free survival (PFS). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Blood samples from 414 patients (<jats:sup>90<\/jats:sup>Y-ibritumomab, n = 208; control, n = 206) were evaluated using real-time quantitative polymerase chain reaction (RQ-PCR); 186 were found to have the bcl-2 rearrangement and were thus eligible for inclusion in the RQ-PCR analysis. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Overall, 90% of treated patients converted from bcl-2 PCR\u2013detectable to \u2013undetectable disease status, compared with 36% in the control group. Treatment significantly prolonged median PFS in patients converting to bcl-2 PCR-undetectable status (40.8 v 24.0 months in the control group; P &lt; .01, hazard ratio [HR], 0.399). In patients who had bcl-2 PCR-detectable disease at random assignment, treatment significantly prolonged median PFS (38.4 v 8.2 months in the control group; P &lt; .01, HR, 0.293). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Eradication of PCR-detectable disease occurred more frequently after treatment with <jats:sup>90<\/jats:sup>Y-ibritumomab tiuxetan and was associated with prolongation of PFS. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2009.22.6258","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T01:43:38Z","timestamp":1256607818000},"page":"6094-6100","source":"Crossref","is-referenced-by-count":35,"title":["Quantitative PCR Analysis for <i>Bcl-2\/IgH<\/i> in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma"],"prefix":"10.1200","volume":"27","author":[{"given":"Lindsey","family":"Goff","sequence":"first","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Summers","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameena","family":"Iqbal","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kunz","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Louton","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hagenbeek","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Putz","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lister","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama","family":"Rohatiner","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Bayer Schering Pharma AG; Dr Notghi Contract Research, Berlin, Germany; University Medical Center Utrecht\/Dutch Hemato-Oncology Group, Utrecht, the Netherlands; and the Centre Hospitalier Universitaire de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2004.06.002"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821215)50:12<2708::AID-CNCR2820501203>3.0.CO;2-G"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900020306"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10894"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198701083160204"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1043.1043"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.1103"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.3874430"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113235"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.16.6961"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.420"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.21.7439"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.14.5214"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1333"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03641.x"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.043"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.143"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2144\/98256cr05"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2490"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11671"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008381105849"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.856"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.9.3081"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0621"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12253"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175653"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2009.22.6258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:14:59Z","timestamp":1653524099000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2009.22.6258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,20]]},"references-count":38,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2009,12,20]]}},"alternative-id":["10.1200\/JCO.2009.22.6258"],"URL":"https:\/\/doi.org\/10.1200\/jco.2009.22.6258","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,20]]}}}